Active Peripheral Spondyloarthritis (pSpA)
1 clinical trials · Condition
◉ Watch Active Peripheral Spondyloarthritis (pSpA)
| Record | Firm | Date |
|---|---|---|
| Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA). (NCT05206591) | Novartis Pharmaceuticals | 2022-08-16 |
Track Active Peripheral Spondyloarthritis (pSpA) automatically
Every clearance here is in the API, with alerts when new ones post.